Merrion Pharma : Novo Nordisk A/S Successfully Completes Single Dose Phase I Trial Oral Insulin (NN1953) Using Merrion Pharmaceuticals GIPET® Technology

03 Febuary 2012

Merrion Pharmaceuticals plc (ESM: MERR), today announces that its partner, Novo Nordisk, successfully completed a single dose Phase I trial with a novel oral insulin (NN1953). Merrion Pharmaceuticals GIPET Technology was used in the formulation of NN1953. Following the successful completion of this trial, Novo Nordisk's planning of a multiple dose study is on